» Articles » PMID: 28153383

Non-Hodgkin Lymphoma

Overview
Journal Lancet
Publisher Elsevier
Specialty General Medicine
Date 2017 Feb 4
PMID 28153383
Citations 255
Authors
Affiliations
Soon will be listed here.
Abstract

Lymphomas can affect any organ in the body, present with a wide range of symptoms, and be seen by primary care physicians and physicians from most specialties. They are traditionally divided into Hodgkin's lymphoma (which accounts for about 10% of all lymphomas) and non-Hodgkin lymphoma, which is the topic of this Seminar. Non-Hodgkin lymphoma represents a wide spectrum of illnesses that vary from the most indolent to the most aggressive malignancies. They arise from lymphocytes that are at various stages of development, and the characteristics of the specific lymphoma subtype reflect those of the cell from which they originated. Since this topic was last reviewed in The Lancet in 2012, advances in understanding the biology and genetics of non-Hodgkin lymphoma and the availability of new diagnostic methods and therapies have improved our ability to manage patients with this disorder.

Citing Articles

Circulating tumor DNA in lymphoma: technologies and applications.

Fu L, Zhou X, Zhang X, Li X, Zhang F, Gu H J Hematol Oncol. 2025; 18(1):29.

PMID: 40069858 PMC: 11900646. DOI: 10.1186/s13045-025-01673-7.


Cardiopulmonary Functional Profiles in Cancer Therapy-Related Cardiac Dysfunction Among Patients with Non-Hodgkin Lymphoma.

Bursacovschi D, Revenco V, Robu M, Arnaut O Diagnostics (Basel). 2025; 15(4).

PMID: 40002568 PMC: 11854496. DOI: 10.3390/diagnostics15040417.


Global, regional and national temporal trends in incidence and mortality of non-Hodgkin lymphoma from 1992 to 2021: an age-period-cohort analysis.

Tang S, Cao J, Jiang D, Zhu L, Luo Z, Shan S Ann Hematol. 2025; .

PMID: 39992428 DOI: 10.1007/s00277-025-06261-w.


FCRL1 and BAFF mRNA Expression as Novel Diagnostic and Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma: Expression Signatures Predict R-CHOP Therapy Response and Survival.

Al-Amodi H, Bedair H, Gohar S, Mohamed D, Abd El Gayed E, Nazih M Int J Mol Sci. 2025; 26(3).

PMID: 39941037 PMC: 11818594. DOI: 10.3390/ijms26031269.


Survival analysis of a 16-year cohort of follicular lymphoma patients receiving systemic treatment in Brazil.

Azevedo P, Zuppo Laper I, Oliveira D, Sabino A, Garcia M, de Freitas I Front Pharmacol. 2025; 15:1414244.

PMID: 39867655 PMC: 11758161. DOI: 10.3389/fphar.2024.1414244.